Featured Research

from universities, journals, and other organizations

Useful biomarkers for esophageal squamous cell carcinoma

Date:
January 25, 2011
Source:
World Journal of Gastroenterology
Summary:
A research team from China investigated the expression profile of miRNA in esophageal squamous cell carcinoma (ESCC). They found that miRNAs were deregulated and miR-143 and miR-145 were downregulated in ESCC.

MicroRNAs (miRNAs) regulate gene expression by mainly binding to the 3′-UTR of target mRNAs, leading to mRNA degradation or translation inhibition. Esophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancies in China. Many studies have reported the miRNA expression profiles in Barrett's esophagus and esophageal adenocarcinoma. However, the pathobiological significance of aberrant miRNA expression in human ESCC has not been well documented.

A research article to be published on January 7, 2011 in the World Journal of Gastroenterology addresses this question. The authors reported the expression profile of miRNA in ESCC and investigated the expression and functions of miR-143 and miR-145 in ESCC.

The results showed that miRNAs were deregulated and miR-143 and miR-145 were downregulated in ESCC. Furthermore, rescued expression of miR-143 and miR-145 can inhibit cell mobility.

This study provides the first evidence for the anti-oncogenic activity of miR-143 and miR-145 in the development of esophageal squamous cell cancer. Targets of these two miRNAs remain to be defined. These results indicate that miRNAs may eventually constitute useful biomarkers as well as therapeutic targets.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Wu BL, Xu LY, Du ZP, Liao LD, Zhang HF, Huang Q, Fang GQ, Li EM. MiRNA profile in esophageal squamous cell carcinoma: Downregulation of miR-143 and miR-145. World Journal of Gastroenterology, 2011; 17 (1): 79 DOI: 10.3748/wjg.v17.i1.79

Cite This Page:

World Journal of Gastroenterology. "Useful biomarkers for esophageal squamous cell carcinoma." ScienceDaily. ScienceDaily, 25 January 2011. <www.sciencedaily.com/releases/2011/01/110125103911.htm>.
World Journal of Gastroenterology. (2011, January 25). Useful biomarkers for esophageal squamous cell carcinoma. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/01/110125103911.htm
World Journal of Gastroenterology. "Useful biomarkers for esophageal squamous cell carcinoma." ScienceDaily. www.sciencedaily.com/releases/2011/01/110125103911.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins